Cisen Pharmaceutical Co., Ltd.

XSSC:603367 Stock Report

Market Cap: CN¥6.3b

Cisen Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Cisen Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.1% per year. Cisen Pharmaceutical's return on equity is 9.1%, and it has net margins of 12.4%.

Key information

0.5%

Earnings growth rate

0.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.1%
Return on equity9.1%
Net Margin12.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cisen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:603367 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,2555291,499392
30 Jun 244,3135281,568399
31 Mar 244,4775281,580383
31 Dec 234,4625211,603375
30 Sep 234,3644481,609349
30 Jun 234,4224301,650340
31 Mar 234,3314091,701362
31 Dec 224,0663501,557335
30 Sep 223,9373411,490330
30 Jun 223,8153361,430327
31 Mar 223,7793221,426330
31 Dec 213,7833341,456334
30 Sep 213,7813991,396332
30 Jun 213,8484421,404301
31 Mar 213,7254411,402311
31 Dec 203,6744391,351310
30 Sep 203,7674291,486323
30 Jun 203,8154411,480312
31 Mar 203,9434931,459270
31 Dec 194,1135151,490311
30 Sep 194,0135391,275366
30 Jun 193,8935211,224395
31 Mar 193,8535111,233388
31 Dec 183,8085041,242326
30 Sep 183,7905391,331190
30 Jun 183,5864751,176238
31 Mar 183,3634361,040189
31 Dec 172,963367898142
30 Sep 172,820287790124
31 Dec 162,5652477160
31 Dec 152,4972475720
31 Dec 142,3882205570
31 Dec 132,2062085410

Quality Earnings: 603367 has high quality earnings.

Growing Profit Margin: 603367's current net profit margins (12.4%) are higher than last year (10.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603367's earnings have grown by 0.5% per year over the past 5 years.

Accelerating Growth: 603367's earnings growth over the past year (18.1%) exceeds its 5-year average (0.5% per year).

Earnings vs Industry: 603367 earnings growth over the past year (18.1%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 603367's Return on Equity (9.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:44
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cisen Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.